
Beyond Air XAIR
$ 0.75
5.76%
Quarterly report 2025-Q4
added 02-13-2026
Beyond Air Book Value 2011-2026 | XAIR
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Beyond Air
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14.3 M | 27.2 M | 42 M | 78.2 M | 30.5 M | 18.1 M | 4.02 M | 1.54 M | -8.38 M | -25.2 K | 4.59 K | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 78.2 M | -8.38 M | 18.9 M |
Quarterly Book Value Beyond Air
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.29 M | 13.1 M | 10.4 M | 14.3 M | 18.4 M | 29.3 M | 17.7 M | 27.2 M | 23.5 M | 28.8 M | 39.1 M | 42 M | - | 63.7 M | 71.4 M | 78.2 M | 90.8 M | 40.9 M | 33.4 M | 30.5 M | 17.2 M | 16.1 M | 18.2 M | 18.1 M | 12 M | 5.52 M | 7.86 M | 4.02 M | 2.46 M | -5.01 M | -1.37 M | 3.68 M | -8.38 M | -6.87 M | -188 K | 872 K | -4.7 M | -4.7 M | -4.7 M | - | -5.3 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 90.8 M | -8.38 M | 19.3 M |
Book Value of other stocks in the Medical devices industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Align Technology
ALGN
|
3.85 B | $ 176.83 | 5.97 % | $ 13.2 B | ||
|
Alphatec Holdings
ATEC
|
791 M | $ 11.66 | 5.71 % | $ 1.75 B | ||
|
GenMark Diagnostics, Inc.
GNMK
|
196 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
-879 K | - | -26.83 % | $ 2.62 M | ||
|
AxoGen
AXGN
|
129 M | $ 34.0 | 9.71 % | $ 1.57 B | ||
|
AdaptHealth Corp.
AHCO
|
1.53 B | $ 12.18 | 2.01 % | $ 1.65 B | ||
|
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | ||
|
Lianluo Smart Limited
LLIT
|
272 M | - | 24.59 % | $ 44.8 M | ||
|
Conformis
CFMS
|
54.2 M | - | - | $ 16.4 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
25.5 M | - | -5.86 % | $ 30.6 M | ||
|
Bio-Rad Laboratories
BIO
|
6.57 B | $ 281.15 | 1.13 % | $ 7.93 B | ||
|
Cardiovascular Systems
CSII
|
249 M | - | 0.15 % | $ 844 M | ||
|
Cytosorbents Corporation
CTSO
|
5.9 M | $ 0.62 | 1.67 % | $ 38.6 M | ||
|
Bruker Corporation
BRKR
|
1.82 B | $ 38.25 | 4.31 % | $ 5.7 K | ||
|
Boston Scientific Corporation
BSX
|
43.7 B | $ 62.56 | 1.15 % | $ 92.6 B | ||
|
Dynatronics Corporation
DYNT
|
3.26 M | - | 14.99 % | $ 929 K | ||
|
Apollo Endosurgery
APEN
|
32.6 M | - | - | $ 475 M | ||
|
Electromed
ELMD
|
43.2 M | $ 24.4 | 2.61 % | $ 206 M | ||
|
Second Sight Medical Products
EYES
|
15.7 M | - | -0.97 % | $ 54.4 M | ||
|
ClearPoint Neuro
CLPT
|
28 M | $ 9.17 | 1.1 % | $ 260 M | ||
|
GBS
GBS
|
2.81 M | - | -0.57 % | $ 7.12 M | ||
|
Globus Medical
GMED
|
4.57 B | $ 91.96 | 2.13 % | $ 12.4 B | ||
|
CryoLife, Inc.
CRY
|
58.1 M | - | -4.14 % | $ 702 M | ||
|
Avinger
AVGR
|
-6.2 M | - | -20.74 % | $ 369 K | ||
|
CHF Solutions, Inc.
CHFS
|
6.23 M | - | 1.15 % | $ 34.5 M | ||
|
Inogen
INGN
|
192 M | $ 6.67 | -1.91 % | $ 177 M | ||
|
Inspire Medical Systems
INSP
|
781 M | $ 53.38 | -1.89 % | $ 1.57 B | ||
|
Axonics Modulation Technologies
AXNX
|
570 M | - | - | $ 3.31 B | ||
|
IRIDEX Corporation
IRIX
|
4.92 M | $ 1.03 | - | $ 17.4 M | ||
|
Integer Holdings Corporation
ITGR
|
1.75 B | $ 87.48 | 2.78 % | $ 3.04 B | ||
|
Invacare Corporation
IVC
|
771 M | - | - | $ 24.7 M | ||
|
Aziyo Biologics
AZYO
|
27.7 M | - | 1.37 % | $ 20.5 M | ||
|
Soliton, Inc.
SOLY
|
243 M | - | -1.42 % | $ 435 M | ||
|
OrthoPediatrics Corp.
KIDS
|
347 M | $ 16.01 | 1.59 % | $ 376 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
2.61 B | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
229 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
30.4 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
52.2 M | - | - | $ 111 M | ||
|
LivaNova PLC
LIVN
|
1.2 B | $ 64.66 | 1.76 % | $ 3.53 B | ||
|
LENSAR
LNSR
|
-12.2 M | $ 5.53 | -1.78 % | $ 66.1 M | ||
|
Butterfly Network
BFLY
|
169 M | $ 4.14 | 2.22 % | $ 876 M | ||
|
Intersect ENT, Inc.
XENT
|
550 M | - | - | $ 955 M | ||
|
EDAP TMS S.A.
EDAP
|
56.9 M | $ 3.37 | -0.88 % | $ 126 M | ||
|
Myomo
MYO
|
11.4 M | $ 0.68 | 0.44 % | $ 28.5 M | ||
|
NanoVibronix
NAOV
|
627 K | - | - | $ 1.08 M | ||
|
BIOLASE
BIOL
|
1.96 M | - | -13.19 % | $ 166 K | ||
|
Delcath Systems
DCTH
|
111 M | $ 9.85 | 1.86 % | $ 353 M | ||
|
BioSig Technologies
BSGM
|
133 M | - | 37.08 % | $ 85.7 M | ||
|
Natus Medical Incorporated
NTUS
|
425 M | - | 1.94 % | $ 1.05 B | ||
|
Nevro Corp.
NVRO
|
231 M | - | - | $ 217 M |